Charles Williams brings 20 years of biopharmaceutical industry experience across various leadership positions in strategy, operations, finance and corporate development. He most recently headed corporate development at Jazz Pharmaceuticals plc. Previously, he held various corporate development and finance roles at MAP Pharmaceuticals (acquired by Allergan) and CV Therapeutics (acquired by Gilead). He started his career in biopharmaceutical consulting and investment banking. Mr. Williams earned a B.A. in economics from Cornell University.